Cesare Astori

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Elisa Rumi, Daniela Pietra, Virginia Valeria Ferretti et al. · Blood · 2013 · 585 citations · Full text

Medicine, Genetics, Hematology +13

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Elisa Rumi, Daniela Pietra, Cristiana Pascutto et al. · Blood · 2014 · 383 citations · Full text

Medicine, Genetics, Hematology +16

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

Elisa Rumi, Daniela Pietra, Paola Guglielmelli et al. · Blood · 2013 · 93 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.

Ercole Brusamolino, Francesca Lunghi, Ester Orlandi et al. · PubMed · 2000 · 80 citations

Medicine, Oncology, Radiation Oncology +11

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra et al. · Blood · 2014 · 72 citations · Full text

Medicine, Genetics, Hematology +11